Skip to content

A Clinical Study for People with Cystic Fibrosis (CF)

Who Have Specific Mutations in the CFTR Gene, Which Are the Cause of CF

This clinical study is exploring a potential new inhaled mRNA treatment called RCT2100 that may improve the function of the CFTR protein in the lungs, getting at the root cause of CF rather than just controlling symptoms.

Here, you will find more information about the study, investigational medicine, and how you, or someone you know, can participate.

About Cystic Fibrosis

CF is a progressive genetic disease that causes persistent lung infections and respiratory failure. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and impacts approximately 130,000 people worldwide.

The absence or dysfunction of the CFTR protein results in a defect in airway hydration, which leads to excessive mucus buildup in the lungs. It also creates a mucociliary clearance defect, recurrent infections, inflammation, respiratory failure, and other complications.

Despite the availability of CFTR modulators that work for 90% of people with CF, many will not be able to take the medication due to side effects, lack of response, or other reasons. About 10% of the CF community have genetic mutations that do not benefit from these therapeutics.

CF impacts approximately 130,000 people worldwide. 90% respond to CFTR modulators, and 10% do not.

Why this Study is Important

No CFTR modulator therapies are currently approved to treat individuals with certain mutations in the CFTR gene because these mutations prevent the production of any CFTR protein.

Without CFTR protein, there is nothing available for the therapy to correct. This study aims to find out whether the investigational study medicine is safe and may work as a potential new treatment option for people with CF who are not eligible for current CFTR modulator therapy.

To learn more, contact:

[email protected]

How the Study Medicine Works

ReCode is developing RCT2100, an investigational inhaled therapy for cystic fibrosis (CF) based on messenger RNA (mRNA). This treatment is designed to deliver CFTR mRNA directly to target cells in the lungs, instructing them to produce a functional version of the CFTR protein.

By providing CFTR mRNA to individuals with CF who are missing this protein, the therapy aims to address the underlying cause of the disease, potentially improving CFTR protein function in the lungs rather than just managing symptoms.

How the Study Medicine is Given

The investigational study medicine, RCT2100, will be given using a nebulizer — a medical device that converts liquid medication into a mist for inhalation.

1 Screening

There will be a 2–4-hour office visit to determine your eligibility to participate.

2 Treatment

If you are eligible, you will receive inhaled doses of RCT2100.

3 Follow-up

After your last dose, there will be a 24-week follow-up period, which includes a final outpatient visit.

Study tests and procedures

Throughout the study, you will have certain exams and tests, including:

Physical Exam

Vital Signs Measurement

Electrocardiogram
A non-invasive test to record the heart’s electrical activity

Chest X-Ray
(if you have not had one within six months)

Pulse oximetry
A non-invasive test that measures oxygen in the blood
Spirometry and Lung Diffusion Testing
A non-invasive test to measure how much and how fast you can move air into and out of your lungs and how well your lungs are exchanging gases

Blood and Urine Tests

You will be given more details in the informed consent document that you will need to sign if you choose to participate in the study.

Eligibility

Who Can Participate
  • Those who are 18-65 years old
  • Those with a diagnosis of CF
  • CF patients not eligible for treatment with CFTR modulators based on having mutations of the CFTR gene or CF patients who are eligible, but not able to tolerate CFTR modulators
  • Anyone with an expiratory volume (FEV1) greater than 40% predicted
  • Those willing to use contraception
Who Cannot Participate
  • Those who are pregnant or breastfeeding
  • Anyone who has received treatment with a CFTR modulator in the last 12 weeks
  • Those who have had a CF pulmonary exacerbation in the last 4 weeks
  • Anyone with a lung infection caused by organisms including B. cenocepacia, B. dolosa or M. abscessus
  • An oxygen saturation <94% on room air

FAQs

What is a clinical research study?

A clinical research study is a carefully designed investigation to assess the safety, effectiveness, and potential benefits of medical treatments, interventions, or procedures in humans. These studies are essential for advancing medical knowledge and improving patient care.

Participants in a clinical study may receive new investigational treatments and are closely monitored to observe their responses and outcomes. The studies follow strict ethical guidelines and regulatory requirements to ensure the safety and rights of participants.

By participating in a clinical research study, patients contribute to developing new medical therapies and may gain access to innovative treatments that might not yet be widely available.

Many study sites are enrolling in the U.S. and U.K., as well as in France and the Netherlands. Click here to find a list of all available study sites.

If you are eligible and decide to participate in the study, a study doctor will share more information about the time expected from you during the study.

There are three parts to the study:

  1. Screening period: involves a 2–4-hour office visit to determine your eligibility to participate.
  2. Treatment period: will take 4 weeks where you will receive RCT2100
  3. Follow-up period: will take 24 weeks.

If you participate, you can expect to be in the study for about 28 weeks (~7 months).

You will be reimbursed for completion of the study.
There will be no cost for you to participate. ReCode will pay for all required tests, procedures, travel, and accommodations

Participating may involve some potential risks, which may occur from the investigational study medicine or the tests.

You will receive an informed consent form describing the full risks involved before agreeing to participate in the study.

The study doctor will also discuss risks with you and answer any questions that you may have about the study.

Participating in a clinical research study for CF may contribute to the advancement of medical science, helping to develop new treatments for CF that can benefit others in the future.

With the study doctor’s approval, this trial offers a home visit option. This option allows for dosing at your home, carried out by a qualified nurse trained to administer RCT2100 after you receive your first two doses. The nurse will arrive one hour before dosing and remain at your home one-hour post-dose.
You may withdraw your consent from the study at any time after signing the consent form without giving a reason and without impacting your ongoing healthcare from your physician.

The study doctor at the trial site will oversee your care during the study. You may also continue to see your regular healthcare providers for routine healthcare.

They will work with the study team to ensure the clinical trial does not conflict with any medications or treatments you may currently be receiving.

To find out more, contact:

[email protected]